Filtered By:
Specialty: Allergy & Immunology
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 296 results found since Jan 2013.
Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer
Vaccine. 2023 Sep 11:S0264-410X(23)00990-8. doi: 10.1016/j.vaccine.2023.08.047. Online ahead of print.ABSTRACTIndividuals with human papillomavirus (HPV)-related disease remain at risk for subsequent HPV infection and related disease after treatment of specific lesions. Prophylactic HPV vaccines have shown benefits in preventing subsequent HPV-related disease when administered before or soon after treatment. Based on our understanding of the HPV life cycle and vaccine mechanism of action, prophylactic HPV vaccination is not expected to clear active persistent HPV infection or unresected HPV-associated dysplastic tissue rem...
Source: Vaccine - September 13, 2023 Category: Allergy & Immunology Authors: Miriam Reuschenbach John Doorbar Marta Del Pino Elmar A Joura Caroline Walker Rosybel Drury Andreas Rauscher Alfred J Saah Source Type: research
Corrigendum to "Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis" Vaccine 40(41) (2022) 5971-5996
Vaccine. 2023 Sep 1:S0264-410X(23)00787-9. doi: 10.1016/j.vaccine.2023.06.084. Online ahead of print.NO ABSTRACTPMID:37659892 | DOI:10.1016/j.vaccine.2023.06.084
Source: Vaccine - September 2, 2023 Category: Allergy & Immunology Authors: Matthew Palmer Kota Katanoda Eiko Saito Cecilia Acuti Martellucci Shiori Tanaka Sayaka Ikeda Haruka Sakamoto Dorothy Machalek Julia M L Brotherton Jane S Hocking Source Type: research
A comparison of electronic health records and the Oregon state immunization registry for human papilloma virus vaccine delivery (2005-2022)
CONCLUSIONS: ALERT IIS data provides more accurate data than EHRs can provide when measuring vaccine delivery among adolescents in rural Oregon.PMID:37573204 | DOI:10.1016/j.vaccine.2023.08.017
Source: Vaccine - August 12, 2023 Category: Allergy & Immunology Authors: Sarah Bumatay Caitlin Dickinson Rex Larsen Isabel Stock Michael R Day Brigit Hatch Steven Robison Paul M Darden Eliana Sullivan Patricia A Carney Source Type: research
Applying the COM-B behaviour model to understand factors which impact school immunisation nurses' attitudes towards designing and delivering a HPV educational intervention in post-primary schools for 15-17 year old students in Northern Ireland, UK
CONCLUSION: IMNs feel that they are the most appropriate professionals to design/deliver HPV education for 15-17 year old students. National policy change, based on collaboration between the Public Health Agency and Education Authority, is a key factor in facilitating IMNs to implement this school-based HPV education intervention.PMID:37543445 | DOI:10.1016/j.vaccine.2023.07.066
Source: Vaccine - August 5, 2023 Category: Allergy & Immunology Authors: Terri Flood Marian McLaughlin Ciara M Hughes Iseult M Wilson Source Type: research
Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030
Vaccine. 2023 Aug 1:S0264-410X(23)00854-X. doi: 10.1016/j.vaccine.2023.07.033. Online ahead of print.ABSTRACTBACKGROUND: The Immunization Agenda 2030 (IA2030) Impact Goal 1.1. aims to reduce the number of future deaths averted through immunization in the next decade. To estimate the potential impact of the aspirational coverage targets for IA2030, we developed an analytical framework and estimated the number of deaths averted due to an ambitious vaccination coverage scenario from 2021 to 2030 in 194 countries.METHOD: A demographic model was used to determine annual age-specific mortality estimates associated with vaccine c...
Source: Vaccine - August 3, 2023 Category: Allergy & Immunology Authors: Austin Carter William Msemburi So Yoon Sim Katy A M Gaythorpe Philipp Lambach Ann Lindstrand Raymond Hutubessy Source Type: research
Dual anti-PD-(L)1/TGF- β inhibitors in cancer immunotherapy - Updated
Int Immunopharmacol. 2023 Jul 15;122:110648. doi: 10.1016/j.intimp.2023.110648. Online ahead of print.ABSTRACTImmune checkpoint inhibitor (ICI) therapy suffers from tumor resistance and relapse in majority of patients due to the suppressive tumor immune microenvironment (TIME). Advances in the field have brought about development of fusion proteins able to target two signaling simultaneously and to exert maximal anti-cancer immunity. Bispecific inhibitors of transforming growth factor (TGF)-β signaling and programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) are developed to reduce the rate of relapse and to ach...
Source: International Immunopharmacology - July 17, 2023 Category: Allergy & Immunology Authors: Zana Karami Keywan Mortezaee Jamal Majidpoor Source Type: research
Opportunities to accelerate immunization progress in middle-income countries
Vaccine. 2023 Jul 15:S0264-410X(23)00782-X. doi: 10.1016/j.vaccine.2023.06.079. Online ahead of print.ABSTRACTThere has been increasing recognition of vaccine access challenges in middle-income countries and the need for increased action, particularly in countries that are not eligible for or have transitioned out of Gavi, the Vaccine Alliance support. These countries' immunization systems are more vulnerable than ever as the COVID-19 pandemic exacerbates existing programme challenges, increasing the risk of delayed vaccine introductions, backsliding immunization coverage rates, and increased coverage inequity. The potenti...
Source: Vaccine - July 17, 2023 Category: Allergy & Immunology Authors: Jason Zhu Clarke B Cole Johanna Fihman Alex Adjagba Mira Dasic Tania Cernuschi Source Type: research
A time-resolved fluorescence immunoassay for rapid and precise automatic quality control of human papillomavirus type 68 VLPs in human papillomavirus vaccine
J Immunol Methods. 2023 Jun 27:113518. doi: 10.1016/j.jim.2023.113518. Online ahead of print.ABSTRACTThe effectiveness and necessity of human papillomavirus (HPV) vaccination to prevent HPV infection and cervical cancer are increasingly recognized by people. The 15-valent HPV vaccine, which protects against almost high-risk types of HPV viruses identified by WHO, has attracted much attention. However, as the valence of vaccines increases, quality control in the HPV vaccine production process is facing more challenges. The precise quality control of the HPV type 68 virus-like particles (VLPs), one of the unique components o...
Source: Journal of Immunological Methods - June 29, 2023 Category: Allergy & Immunology Authors: Zhaoyue Li Muhan Wu Yin Chen Yang Li Zhigao Zhang Xiangming Zhai Yue Cao Xijiu Li Yiqi Yang Yingsong Wu Guanfeng Lin Source Type: research
How can we improve the acceptability of vaccination against Human Papillomavirus (HPV) in France? An original qualitative study with focus groups comprising parents and school staff, interviewed separately
CONCLUSION: The results of these focus groups provided information on which elements may harm or help HPV vaccination. Identified perceptions, beliefs, knowledge, barriers, and facilitators will help us to build an intervention program focus on general practitioners (GP), school staff, parents, and adolescents.PMID:37344259 | DOI:10.1016/j.vaccine.2023.05.072
Source: Vaccine - June 21, 2023 Category: Allergy & Immunology Authors: Julien Ailloud Marion Branchereau Estelle Fall Catherine Juneau Henri Partouche St éphanie Bonnay Damien Oudin-Doglioni Morgane Michel Amandine Gagneux-Brunon S ébastien Bruel Nathalie Thilly Aur élie Gauchet PrevHPV study Group Source Type: research
